{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:23:38Z","timestamp":1790497418677,"version":"4.1.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The prevalence rate of hypertension and breast cancer increases with advancing age. Renin-angiotensin system inhibitors (RASIs), \u03b2-blockers (BBs), calcium channel blockers (CCBs), and diuretics are widely used to treat patients with hypertension. Although, the association between the use of antihypertensive medication and breast cancer has been highly debated, recent evidence supporting this association remains controversial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To evaluate the association between the use of antihypertensive medication and the risk of breast cancer and its prognosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    This study was conducted using data from the PubMed, Embase, and Cochrane Library databases retrieved for the period from January 2000 to April 2021. Articles and their references were checked and summary effects were calculated using random- and fixed-effects models. Heterogeneity test and sensitivity analysis were also performed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    This meta-analysis included 57 articles, which were all related to breast cancer risk or prognosis. Assessment of breast cancer risk using the pooled data showed that the use of BBs or CCBs or diuretics was associated with increased cancer risk [BB: relative risk (RR) = 1.20, 95% confidence interval (CI) = 1.09\u20131.32; CCBs: RR = 1.06, 95% CI 1.03\u20131.08; diuretics: RR = 1.06, 95% CI 1.01\u20131.11]. Long-term use of diuretic increased the risk of breast cancer (RR = 1.10, 95% CI 1.01\u20131.20), whereas long-term RASIs treatment reduced the risk (RR = 0.78, 95% CI 0.68\u20130.91). In addition, we found that diuretic users may be related to elevated breast cancer-specific mortality [hazard ratio (HR) = 1.18, 95% CI 1.04\u20131.33], whereas using other antihypertensive medications was not associated with this prognosis in patients with breast cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Using CCBs, BBs, and diuretics increased the risk of breast cancer. In addition, diuretics may elevate the risk of breast cancer-specific mortality. The long-term use of RASIs was associated with a significantly lower breast cancer risk, compared with non-users. Thus, this analysis provides evidence to support the benefits of the routine use of RASIs in patients with hypertension, which has important public health implications.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.609901","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T05:52:01Z","timestamp":1620885121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuxiu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Men","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/ede.0000000000000483","article-title":"Use of Calcium Channel Blockers and Risk of Breast Cancer","volume":"27","author":"Azoulay","year":"2016","journal-title":"Epidemiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10549-013-2654-3","article-title":"The Effect of Renin-Angiotensin-System Inhibition on Survival and Recurrence of N3+ Breast Cancer Patients","volume":"20","author":"Babacan","year":"2015","journal-title":"J. Buon"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/jco.2010.33.5422","article-title":"Beta Blockers and Breast Cancer Mortality: a Population\u2014Based Study","volume":"29","author":"Barron","year":"2011","journal-title":"Jco"},{"key":"B4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone Use and the Risk of Breast and Gynecologic Cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-013-2654-3","article-title":"Therapeutic Effect of \u03b2-blockers in Triple-Negative Breast Cancer Postmenopausal Women","volume":"140","author":"Botteri","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-014-2870-5","article-title":"Comparative Safety of Cardiovascular Medication Use and Breast Cancer Outcomes Among Women with Early Stage Breast Cancer","volume":"144","author":"Boudreau","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1055-9965.Epi-17-0096","article-title":"Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative","volume":"26","author":"Brasky","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ede.0000000000000814","article-title":"Postdiagnostic Calcium Channel Blocker Use and Breast Cancer Mortality","volume":"29","author":"Busby","year":"","journal-title":"Epidemiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/pds.4345","article-title":"A Combined Connectivity Mapping and Pharmacoepidemiology Approach to Identify Existing Medications with Breast Cancer Causing or Preventing Properties","volume":"27","author":"Busby","year":"","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.esmoop.2021.100066","article-title":"Beta-blockers in Early-Stage Breast Cancer: a Systematic Review and Meta-Analysis","volume":"6","author":"Caparica","year":"2021","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ije\/dyt196","article-title":"Beta-blocker Usage and Breast Cancer Survival: a Nested Case-Control Study within a UK Clinical Practice Research Datalink Cohort","volume":"42","author":"Cardwell","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1741-7015-12-28","article-title":"Drugs Affecting the Renin-Angiotensin System and Survival from Cancer: a Population Based Study of Breast, Colorectal and Prostate Cancer Patient Cohorts","volume":"12","author":"Cardwell","year":"2014","journal-title":"BMC Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13058-016-0782-5","article-title":"Propranolol and Survival from Breast Cancer: A Pooled Analysis of European Breast Cancer Cohorts","volume":"18","author":"Cardwell","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7150\/jca.6888","article-title":"Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes","volume":"4","author":"Chae","year":"2013","journal-title":"J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/hjh.0000000000000813","article-title":"Antihypertensive Agents and the Risk of Breast Cancer in Women Aged 55 Years and Older","volume":"34","author":"Chang","year":"2016","journal-title":"J. Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","article-title":"Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population","volume":"26","author":"Chen","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1055-9965.Epi-15-0547","article-title":"Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer Among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer","volume":"24","author":"Chen","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3892\/or.2016.4710","article-title":"Inhibition of \u03b22-adrenergic Receptor Reduces Triple-Negative Breast Cancer Brain Metastases: The Potential Benefit of Perioperative \u03b2-blockade","volume":"35","author":"Choy","year":"2016","journal-title":"Oncol. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jamainternmed.2013.9069","article-title":"Calcium-Channel Blockers and Breast Cancer","volume":"173","author":"Coogan","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jhh.2008.131","article-title":"Diuretic Use and the Risk of Breast Cancer","volume":"23","author":"Coogan","year":"2009","journal-title":"J. Hum. Hypertens."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/aje\/kwz106","article-title":"Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer","volume":"188","author":"Cui","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.04.019","article-title":"Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trial Evidence Refutes Relationship between Pharmacotherapy with Angiotensin-Receptor Blockers and an Increased Risk of Cancer","volume":"64","author":"Datzmann","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10654-007-9135-0","article-title":"Medication Use and the Risk of Breast Cancer","volume":"22","author":"Davis","year":"2007","journal-title":"Eur. J. Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-015-3311-9","article-title":"Antihypertensive Medication Use and Incident Breast Cancer in Women","volume":"150","author":"Devore","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in Meta-Analysis Detected by a Simple, Graphical Test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(15)01225-8","article-title":"Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: a Systematic Review and Meta-Analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"The Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","article-title":"A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women","volume":"97","author":"Fryzek","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","article-title":"Examining the Influence of Beta Blockers and ACE Inhibitors on the Risk for Breast Cancer Recurrence: Results from the LACE Cohort","volume":"129","author":"Ganz","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The Renin-Angiotensin System and Cancer: Old Dog, New Tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0159672","DOI":"10.1371\/journal.pone.0159672","article-title":"The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study","volume":"11","author":"G\u00f3mez-Acebo","year":"2016","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pds.910","article-title":"Breast Cancer Incidence and Use of Antihypertensive Medication in Women","volume":"13","author":"Gonz\u00e1lez-P\u00e9rez","year":"2004","journal-title":"Pharmacoepidem. Drug Safe."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e113649","DOI":"10.1371\/journal.pone.0113649","article-title":"Nifedipine Promotes the Proliferation and Migration of Breast Cancer Cells","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long Term Use of Drugs Affecting the Renin-Angiotensin System and the Risk of Cancer: a Population-Based Case-Control Study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"44877","DOI":"10.1038\/srep44877","article-title":"Hypertension and Breast Cancer Risk: a Systematic Review and Meta-Analysis","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ygyno.2008.02.019","article-title":"Potential Role of Renin-Angiotensin-System for Tumor Angiogenesis in Receptor Negative Breast Cancer","volume":"109","author":"Herr","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-013-2553-7","article-title":"Beta Blockers and Angiotensin-Converting Enzyme Inhibitors' Purported Benefit on Breast Cancer Survival May Be Explained by Aspirin Use","volume":"139","author":"Holmes","year":"","journal-title":"Breast Cancer Res. Treat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive Medications and Survival in Patients with Cancer: a Population-Based Retrospective Cohort Study","volume":"37","author":"Holmes","year":"","journal-title":"Cancer Epidemiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","article-title":"Angiotensin II Receptor Blockers and Risk of Cancer in Patients with Systemic Hypertension","volume":"107","author":"Huang","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/emboj.2010.346","article-title":"Fis1 and Bap31 Bridge the Mitochondria-ER Interface to Establish a Platform for Apoptosis Induction","volume":"30","author":"Iwasawa","year":"2011","journal-title":"Embo j"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10552-010-9590-x","article-title":"Hypertension, Antihypertensive Medication Use, and Breast Cancer Risk in the California Teachers Study Cohort","volume":"21","author":"Largent","year":"2010","journal-title":"Cancer Causes Control"},{"key":"B42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, Diuretics and Breast Cancer Risk","volume":"20","author":"Largent","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"B43","doi-asserted-by":"publisher","first-page":"A654","DOI":"10.1016\/j.jval.2012.08.305","article-title":"PCN7 Angiotensin-Converting Enzyme Inhibitors Enhance the Effect of Cyclooxygenase Inhibitors on Breast Cancer: A Nationwide Case-Control Study","volume":"15","author":"Lee","year":"2012","journal-title":"Value in Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55\u201374 Years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between Use of Antihypertensive Medications and Risk of Breast Carcinoma Among Women Ages 65\u201379 Years","volume":"98","author":"Li","year":"2003","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological Quality (Risk of Bias) Assessment Tools for Primary and Secondary Medical Studies: what Are They and Which Is Better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and Risk of Incident Breast Cancer in Women Older Than 55 years: Retrospective, Matched Cohort Study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/archinte.160.3.349","article-title":"Angiotensin-converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer","volume":"160","author":"Meier","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/jco.2010.33.4441","article-title":"Beta-blocker Use is Associated with Improved Relapse-free Survival in Patients with Triple-Negative Breast Cancer","volume":"29","author":"Melhem-Bertrandt","year":"2011","journal-title":"J Clin Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3389\/fonc.2020.01130","article-title":"The Influence of Pre-existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data","volume":"10","author":"Modi","year":"2020","journal-title":"Front. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ejso.2018.05.012","article-title":"Association between Perioperative Beta Blocker Use and Cancer Survival Following Surgical Resection","volume":"44","author":"Musselman","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.22038\/IJOGI.2020.16884","article-title":"Effect of Renin-Angiotensin System Inhibitors on Survival Rate of Patients with Breast Cancer: Systematic Review and Meta-Analysis","volume":"26","author":"Naghibzadeh","year":"2020","journal-title":"Iranian J. Obstet. Gynecol. Infertility"},{"key":"B53","doi-asserted-by":"publisher","first-page":"62545","DOI":"10.18632\/oncotarget.19117","article-title":"Antihypertensive Drug Use and Breast Cancer Risk: a Meta-Analysis of Observational Studies","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/cej.0000000000000218","article-title":"Adrenergic Blockers and the Risk for Common Solid Cancers: a Case-Control Study","volume":"26","author":"Numbere","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"18","author":"Page","year":"2021","journal-title":"Plos Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.197","article-title":"Beta-blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget"},{"key":"B57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/aje\/kww217","article-title":"Risk of Breast Cancer with Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women","volume":"185","author":"Raebel","year":"2017","journal-title":"Am. J. Epidemiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000371871","article-title":"\u03b2-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer","volume":"60","author":"Sakellakis","year":"2014","journal-title":"Chemotherapy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10552-012-0122-8","article-title":"Use of Antihypertensive Medications and Breast Cancer Risk","volume":"24","author":"Saltzman","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/1055-9965.Epi-20-0711","article-title":"Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland","volume":"29","author":"Santala","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11892-007-0031-5","article-title":"Antihypertensive Agents, Insulin Sensitivity, and New-Onset Diabetes","volume":"7","author":"Sarafidis","year":"2007","journal-title":"Curr. Diab Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.breast.2012.01.01010.1016\/j.breast.2011.09.015","article-title":"Efficacy of Angiotensin-Receptor Blockers on Demographic and Clinico-Pathological Characteristics of Breast Cancer","volume":"21","author":"\u015eendur","year":"2012","journal-title":"Breast"},{"key":"B63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2125.2011.03980.x","article-title":"Does \u03b2-adrenoceptor Blocker Therapy Improve Cancer Survival? Findings from a Population-Based Retrospective Cohort Study","volume":"72","author":"Shah","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/jcph.1579","article-title":"Protective Association between Calcium Channel Blocker Use and Breast Cancer Recurrence in Postsurgical Women: A Population\u2010Based Case\u2010Control Study in Taiwan","volume":"60","author":"Shih","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1200\/jco.2012.43.9190","article-title":"Use of \u03b2-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study","volume":"31","author":"S\u00f8rensen","year":"2013","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::aid-cncr21>3.0.co;2-g","article-title":"Cancer Risk and Mortality in Users of Calcium Channel Blockers. A Cohort Study","volume":"89","author":"S\u00f8rensen","year":"2000","journal-title":"Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdx264","article-title":"Beta Blockers and Improved Progression-free Survival in Patients with Advanced HER2 Negative Breast Cancer: A Retrospective Analysis of the ROSE\/TRIO-012 Study","volume":"28","author":"Spera","year":"2017","journal-title":"Ann. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e007299","DOI":"10.1136\/bmjopen-2014-007299","article-title":"Can Analyses of Electronic Patient Records Be Independently and Externally Validated? Study 2\u2014the Effect of\u2014adrenoceptor Blocker Therapy on Cancer Survival: a Retrospective Cohort Study","volume":"5","author":"Springate","year":"2015","journal-title":"BMJ Open"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/s0140-6736(18)32225-6","article-title":"Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990\u20132017: a Systematic Analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Stanaway","year":"2018","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15548627.2017.1389822","article-title":"A Negative Feedback Regulation of MTORC1 Activity by the Lysosomal Ca2+ Channel MCOLN1 (Mucolipin 1) Using a CALM (Calmodulin)-dependent Mechanism","volume":"14","author":"Sun","year":"2018","journal-title":"Autophagy"},{"key":"B72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12885-019-5828-5","article-title":"Verification of the Effects of Calcium Channel Blockers on the Immune Microenvironment of Breast Cancer","volume":"19","author":"Takada","year":"2019","journal-title":"BMC Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of Telmisartan, Irbesartan, Valsartan, Candesartan, and Losartan on Cancers in 15 Trials Enrolling 138,769 Individuals","volume":"29","author":"Teo","year":"2011","journal-title":"J. Hypertens."},{"key":"B74","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin System Inhibitors, Angiotensin I-Converting Enzyme Gene Insertion\/deletion Polymorphism, and Cancer","volume":"112","author":"Van Der Knaap","year":"2008","journal-title":"Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term Use of Angiotensin II Receptor Blockers and Risk of Cancer: a Population-Based Cohort Analysis","volume":"167","author":"Wang","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","article-title":"Spironolactone Use Does Not Increase the Risk of Female Breast Cancer Recurrence: A Retrospective Analysis","volume":"83","author":"Wei","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term Use of Calcium Channel Blocking Drugs and Breast Cancer Risk in a Prospective Cohort of US and Puerto Rican Women","volume":"18","author":"Wilson","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canep.2017.08.012","article-title":"Calcium Channel Blockers and Breast Cancer Incidence: An Updated Systematic Review and Meta-Analysis of the Evidence","volume":"50","author":"Wright","year":"2017","journal-title":"Cancer Epidemiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3892\/mmr.2017.6818","article-title":"Nifedipine Stimulates Proliferation and Migration of Different Breast Cancer Cells by Distinct Pathways","volume":"16","author":"Zhao","year":"","journal-title":"Mol. Med. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10641963.2017.1288736","article-title":"Effect of Antihypertensive Drugs on Breast Cancer Risk in Female Hypertensive Patients: Evidence from Observational Studies","volume":"40","author":"Zhao","year":"","journal-title":"Clin. Exp. Hypertens."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/1055-9965.Epi-20-1599","article-title":"Beta-blockers Use and Risk of Breast Cancer in Women with Hypertension","volume":"28","author":"Zheng","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.609901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T05:52:05Z","timestamp":1620885125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.609901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":81,"alternative-id":["10.3389\/fphar.2021.609901"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.609901","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"article-number":"609901"}}